i COMMISSION OF THE EUROPEAN COMMUNITIES 
Brussels, 11.12 1996 
COM(96) 563 final 
96/0268 (ACC) 
Proposal for a 
COUNCIL REGULATION (EC) 
Providing for duty free treatment for specified pharmaceutical active ingredients bearing 
an "international nonproprietary name" (INN) from the World Health Organisation and 
specified products used for the manufacture of finished pharmaceuticals and withdrawing 
duty free treatment as pharmaceutical products from certain INNs whose predominate use 
is not pharmaceutical. 
(presented by the Commission) 

EXPLANATORY MEMORANDUM 
1. Pursuant to the conclusions reached in Uruguay Round Record of Discussions 
(L/4740 of 25.3.1994) on duty free treatment for pharmaceutical products, the 
Commission has participated in the first review of the product coverage to include, by 
consensus, additional products for duty free treatment. 
2. The outcome of the review is that 231 pharmaceutical active ingredients bearing an 
"international nonproprietary name" (INN) from the World Health Organisation and 
234_products used for the manufacture of finished pharmaceuticals should be added to 
the list of products already receiving duty free treatment and also that the list of 
specified prefixes and suffixes for salts and esters of INNs should be expanded by 84 
names. 
3. In addition it was concluded that the situation should be rectified in respect of 25 
INNs whose use was predominantly non-pharmaceutical by deleting them from the 
list of INNs receiving duty free treatment. 
4. The Commission proposes in line with other countries granting duty free treatment for 
these additional products as early as possible in 1997 that the duty free treatment shall 
commence from 1.1.97. 
5. For these reasons the Commission proposes that the Council adopt the Regulation 
contained in the Annex to this communication. 
a. 
PROPOSAL FOR A COUNCIL REGULATION (EC) 
Providing for duty free treatment for specified pharmaceutical active ingredients bearing 
an "international nonproprietary name" (INN) from the World Health Organisation and 
specified products used for the manufacture of finished pharmaceuticals and withdrawing 
duty free treatment as pharmaceutical products from certain INNs whose predominant use 
is not pharmaceutical 
THE COUNCIL OF THE EUROPEAN UNION 
Having regard to the Treaty establishing the European Community, and in particular 
Article 113 thereof, 
Having regard to the proposal from the Commission, 
Whereas, in the course of the Uruguay Round negotiations the Community and a number 
of countries discussed duty free treatment of pharmaceutical products; 
Whereas the participants in those discussions concluded that in addition to products 
falling in the Harmonised System (HS) chapter 30 and HS Headings 2936, 2937, 2939 
and 2941, duty free treatment should be given to designated pharmaceutical active 
ingredients bearing an "international nonproprietary name" (INN) from the World Health 
Organisation as well as specified salts, esters and hydrates of such products, and also to 
designated products used for the production and manufacture of finished products; 
Whereas the results of the discussions, as set out in the Record of Discussions1, were 
incorporated into the tariff schedules of the participants annexed to the Marrakesh 
Protocol to GATT 1994; 
Whereas they also concluded that representatives of the WTO members party to the 
Record of discussions would meet under the auspices of the Council for Trade in Goods 
of the WTO, normally at least once every three years - to review the product coverage 
with a view to including, by consensus, additional pharmaceutical products for tariff 
elimination; 
Whereas the first such review has taken place with the conclusion that additional INNs 
and products used for production and manufacture of finished pharmaceuticals should be 
granted duty free treatment and that the list of specified prefixes and suffixes for salts and 
esters of INNs should be expanded; 
Whereas in the context of the review it was concluded that it was appropriate to rectify 
the situation with regard to certain INNs whose use was predominantly non-
pharmaceutical and which had been inadvertently included among those INNs already 
receiving duty free treatment. 
1 GATT Document L/7430 
HAS ADOPTED THIS REGULATION: 
Article 1 
From 1 January 1997 the Community shall also accord duty free treatment for the INNs 
listed in Annex I as well as the salts, esters and hydrates of such products. 
Article 2 
From 1 January 1997 the Community shall also accord duty free treatment for the 
products used in the production and manufacture of pharmaceutical products listed in 
Annex II. 
Article 3 
From 1 January 1997 the specified prefixes and suffixes of INNs eligible for duty free 
treatment shall also include those listed in Annex III. 
Article 4 
From 1 January 1997 the products listed in Annex IV together with the salts, esters and 
hydrates of such products shall no longer benefit from duty free treatment. 
Article 5 
This Regulation shall enter into force on the day following that of its publication in the 
Official Journal of the European Communities. 
This Regulation shall be binding in its entirety and directly applicable in all Member 
states. 
Done at Brussels, 
For the Council 
The President 
\ 
Annex I 
Additional INNs to receive duty free treatment 
Annex II 
Additional pharmaceutical intermediates, ie compounds used for the manufacture of 
finished pharmaceutical products, to receive duty free treatment. 
Annex III 
Additions to the list of prefixes and suffixes which, in combination with the INNs, 
describe salts, esters or hydrates of INNs. 
Annex IV 
INNs which shall no longer benefit from duty free treatment 
FINANCIAL STATEMENT 
Section 1. Financial Implications 
1. Proposal for a Council Regulation providing duty free treatment for 465 
pharmaceutical products and withdrawing duty free treatment from 25 products whose 
predominant use is not pharmaceutical. 
2. Budget heading: (loss of revenue: not known) 
3. Legal basis: Article 113 
4. Description 
The proposal regulation is a consequence of the agreement reached in the Uruguay 
Round to undertake a periodic review of the agreement with a view to including, by 
consensus, additional products for duty free treatment. 
5. Type of revenue: Loss of revenue for duties paid on third country imports. 
6. Change in level of revenue: 
The withdrawal of duty free treatment from products whose use was predominantly 
non-pharmaceutical with subsequent revenue gains will offset a large proportion of 
the revenue loss for duty free treatment being granted to other products. No figures 
are available for the amounts involved but with this element taken into account the 
duty loss is likely to be less than 2 MECU. 
Annex I 
Additional INNs to receive duty free treatment 
•\ 
CN code CAS KW Nam» 
2844 40 30 113716-48-6 iolopride (123 I) 
142481-95-6 technetium (99m Tc) furifosmin 
2846 90 00 131069-91-5 gadoversetamide 
135326-11-3 gadoxetic acid 
138721-73-0 sprodiamide 
2914 40 90 20098-14-0 idramantone 
2916 39 00 71109-09-6 vedaprofen 
2918 30 00 22161-81-5 dexketoprofen 
112665-43-7 seratrodast 
2918 90 90 139403-31-9 pimilprost 
2921 49 90 136236-51-6 rasagiline 
2922 49 70 6582-31-6 dapabutan 
2923 90 00 1794-75-8 laurcetium bromide 
2924 10 00 1675-66-7 adelmidrol 
62304-98-7 thymalfasin 
132787-19-0 tradecamide 
129009-83-2 versetamide 
2924 29 90 147362-57-0 loviride 
94497-51-5 tamibarotene 
2925 19 80 144849-63-8 bisnafide 
2925 20 00 137159-92-3 aptiganel 
2926 90 80 137109-71-8 balazipone 
147076-36-6 laflunimus 
2928 00 90 141579-54-6 fenleuton 
2930 90 16 87573-01-1 salnacedin 
2930 90 70 90357-06-5 bicalutamide 
112573-72-5 dexecadotril 
107023-41-6 pobilukast 
81110-73-8 racecadotril 
2931 00 50 132236-18-1 zifrosilone 
2931 00 80 114084-78-5 ibandronic acid 
124351-85-5 incadronic acid 
63132-39-8 olpadronic acid 
2932 99 70 105674-77-9 lanproston 
2932 99 90 123407-36-3 arteflene 
132017-01-7 bervastatin 
110816-79-0 cromoglicate lisetil 
149494-37-1 ebalzotan 
151581-24-7 iralukast 
113806-05-6 olopatadine 
139110-80-8 zanamivir 
2933 29 90 158682-68-9 elisartan 
116684-92-5 galdansetron 
89371-44-8 imidaprilat 
138402-11-6 irbesartan 
118072-93-8 zoledronic acid 
2933 39 95 119257-34-0 besipirdine 
118248-91-2 fodipir 
155415-08-0 inogatran 
121750-57-0 itameline 
144412-49-7 lamifiban 
155319-91-8 mangafodipir 
150443-71-3 nicanartine 
29876-14-0 nicotredole 
144035-83-6 piclamilast 
137795-35-8 spiroglumide 
147025-53-4 talsaclidine 
149488-17-5 trovirdine 
2933 40 10 127294-70-6 balofloxacin 
143383-65-7 premafloxacin 
143224-34-4 telinavir 
2933 40 90 
2933 40 90 
2933 59 70 
2933 79 00 
2933 90 95 
2934 10 00 
2934 20 90 
2934 90 60 
2934 90 70 
2934 90 80 
2934 90 98 96946-42-8 
158966-92-8 
136668-42-3 
127266-56-2 
106941-25-7 
113852-37-2 
150756-35-7 
119687-33-1 
127759-89-1 
140945-32-0 
134208-17-6 
96604-21-6 
148504-51-2 
115762-17-9 
118420-47-6 
137234-62-9 
151319-34-5 
148396-36-5 
74436-00-3 
143943-73-1 
106730-54-5 
135548-15-1 
145733-36-4 
143343-83-3 
137882-98-5 
114607-46-4 
120511-73-1 
134523-00-5 
128270-60-0 
139481-59-7 
54278-85-2 
105806-65-3 
62568-57-4 
120081-14-3 
142880-36-2 
62732-44-9 
116287-14-0 
112809-51-5 
116644-53-2 
136122-46-8 
144702-17-0 
132036-88-5 
106308-44-5 
144701-48-4 
147059-72-1 
149079-51-6 
128312-51-6 
51287-57-1 
101001-34-7 
136433-51-7 
138742-43-5 
144665-07-6 
150915-41-6 
146939-27-7 
130370-60-4 
133040-01-4 
135202-79-8 
114686-12-3 
132418-36-1 
132418-35-0 
125533-88-2 
127045-41-4 
118292-40-3 
151356-08-0 cisatracurium besilate 
montelukast 
quiflapon 
adatanserin 
adefovir 
cidofovir 
efletirizine 
iganidipine 
lobucavir 
mapinastine 
mazapertine 
ocinaplon 
ripisartan 
ruzadolane 
tagorizine 
voriconazole 
zaleplon 
fradafiban 
geclosporin 
lirequinil 
olprinone 
oxeclosporin 
tasosartan 
toborinone 
abitesartan 
acitazanolast 
anastrozole 
atorvastatin 
bivalirudin 
candesartan 
candocuronium iodide 
efegatran 
emideltide 
goralatide 
ilomastat 
ipidacrine 
lanperisone 
letrozole 
mibefradil 
mipitroban 
pomisartan 
ramosetron 
rufinamide 
telmisartan 
trovafloxacin 
cartasteine 
cinalukast 
denotivir 
pamicogrel 
tazofelone 
zankiren 
lubeluzole 
perospirone 
ziprasidone 
batimastat 
eprosartan 
ilonidap 
imitrodast 
rocepafant 
setipafant 
mofarotene 
pazufloxacin 
tazarotene 
afovirsen 
2935 00 90 
2936 29 90 
2937 10 10 
2937 22 00 
2937 29 90 
2937 99 00 
2939 50 90 
2939 90 90 
2940 00 90 
2941 90 00 
2941 90 00 138298-79-0 
152317-89-0 
153420-96-3 
143393-27-5 
149908-53-2 
150490-85-0 
154361-50-9 
133099-04-4 
137500-42-6 
114030-44-3 
115464-77-2 
141790-23-0 
122254-45-9 
143443-90-7 
82857-82-7 
104454-71-9 
118288-08-7 
138068-37-8 
78994-23-7 
116476-16-5 
148152-63-0 
84558-93-0 
147432-77-7 
139225-22-2 
103255-66-9 
123447-62-1 
131986-45-3 
145781-32-4 
147536-97-8 
136817-59-9 
119905-05-4 
112966-96-8 
125279-79-0 
139133-26-9 
154397-77-0 
139133-27-0 
116649-85-5 
133276-80-9 
146623-69-0 
149556-49-0 
144494-65-5 
139308-65-9 
107753-78-6 
131875-08-6 
9002-68-0 
152923-57-4 
103466-73-5 
144459-70-1 
124478-60-0 
140703-51-1 
133107-64-9 
144743-92-0 
151581-23-6 
132210-43-6 
100324-81-0 
98833-92-2 
135905-89-4 
117086-68-7 
25775-90-0 
133692-55-4 
127785-64-2 
116853-25-9 
122841-10-5 
156131-91-8 alnespirone 
alniditan 
atibeprone 
azalanstat 
azimilide 
berupipam 
capecitabine 
darifenacin 
darsidomine 
dexpemedolac 
elopiprazole 
fozivudine tidoxil 
glenvastatin 
ifetroban 
ilepcimide 
ipenoxazone 
lafutidine 
lepirudin 
levormeloxifene 
levosemotiadil 
napitane 
netivudine 
ontazolast 
panâmesine 
pazinaclone 
prulifloxacin 
xanomeline 
zolasartan 
bosentan 
delavirdine 
delequamine 
domitroban 
ersentilide 
lexipafant 
napsagatran 
nupafant 
ramatroban 
samixogrel 
saprisartan 
susalimod 
tirofiban 
tolafentrine 
zafirlukast 
lexacalcitol 
follitropin alfa 
lutropin alfa 
icometasone enbutate 
rofleponide 
aglepristone 
examorelin 
insulin lispro 
teverelix 
apaxifylline 
cipamfylline 
lisofylline 
stacofylline 
mirisetron 
ricasetron 
zucapsaicin 
seprilose 
basifungin 
cefluprenam 
cefoselis 
dimadectin 
fa 
123997-26-2 eprinomectin 
149951-16-6 lenapenem 
108852-90-0 nemorubicin 
159445-62-2 orientiparcin 
156769-21-0 sanfetrinem 
3001 90 99 120993-53-5 desirudin 
3002 10 91 143653-53-6 abciximab 
156227-98-4 afelimomab 
151763-64-3 capromab 
152923-56-3 dacliximab 
145832-33-3 detumomab 
142864-19-5 enlimomab 
152981-31-2 inolimomab 
150631-27-9 nacolomab tafenatox 
159445-64-4 odulimomab 
147191-91-1 priliximab 
153101-26-9 regavirumab 
148189-70-2 votumumab 
3002 10 95 143090-92-0 anakinra 
143631-61-2 atexakin alfa 
148637-05-2 cilmostim 
154725-65-2 epoetin epsilon 
148363-16-0 epoetin omega 
102786-52-7 eptacog alfa (activated) 
156679-34-4 lenercept 
124146-64-1 mobenakin 
0-00-0 moroctocog alfa 
148641-02-5 muplestim 
139076-62-3 octocog alfa 
0-00-0 plusonermin 
0-00-0 fuladectin 
143831-71-4 dornase alfa 
154248-97-2 imiglucerase 
149394-67-2 ledismase 
156616-23-8 monteplase 
159445-63-3 nateplase 
155773-57-2 pegorgotein 
3911 90 19 95522-45-5 colestilan 
31512-74-0 polixetonium chloride 
3913 90 80 39464-87-4 betasizofiran 
0-00-0 certoparin sodium 
0-00-0 minolteparin sodium 3003 39 00 
3003 90 90 
3507 90 90 
11 
Annex II 
Additional pharmaceutical intermediates, ie compounds used for the manufacture of 
finished pharmaceutical products, to receive duty free treatment. 
43. 
est coda CAS R» game ^^ 
2843 30 00 12192-57-3 (alpha-D-glucopyranosylthioJgold 
2903 69 90 42074-68-0 l-chloro-2-(chlorodiphenylmathyl)benzene 
76283-09-5 alpha,4-dibromo-2-filuorotoluene 
2906 29 90 104265-58-9 2-[(is,2R)-6-fluoro-2-hydroxy-1-isoprdpyl-
l,2,3,4-tetrahydro-2-naphthyllethyl p-
toluenasulfonate 
2907 29 90 700-13-0 2, 3,5-triraethylhydjroquinane 
2909 50 90 63659-16-5 4- [2-(cyclopropylmethoxy)ethyl]phenol 
2914 40 90 80-75-1 ll-alpha-hydroxypregn-4-9ne-3,20-d±ane 
2914 50 00 2107-69-9 5,6-diraethoxyindan-l-one 
24916-90-3 9-beta,11-beta-epoxy-l7,2l-dihydroxy-lS-alpha-
methylpregna-l,4-diene-3,20-dione 
2914 70 90 83881-08-7 21-chloro-9-beta",11-beta-epoxy-17-hydroxy-16-
alpha-methylpregna-1,4-diene-3,20-dione 
2915 39 90 979-02-2 2Q~oxopregna-5,16-dien-3-beta-yl acetate 
2915 90 20 638-41-5 pexityl chloroformate -. -, 
291a 39 00 49708-81-8 trans-4-(p-ahlorophenyl)^yClohexanecarboxylic 
acid 
2917 19 90 48059-97-8 (B) -oct-4-ei»r-l, 8-dloic "acid 
71170-82-6 triethyl 3-bramopropane-l,1,1-tricarboxylate 
2917 39 80 27932-00-9 indan-5-yl hydrogen phenylmalonate 
2918 13 00 2743-38-6 dibenzoyl-L-tartaric acid 
2918 17 00 4358-88-7 ethyl DL-mandel'at* 
2918.19 80 563.88-04-6 {(lit, 3R, 5S) ~3 , 5-dlhydroxy-2- [ (E) - (3S) -3-
hydroxyoct-l-enyl]cyclopentyl}ac«tic acid 
2918 29 90 167678-46-8 3-chloroformyl-o-tolyl acetate 
2918 30-00 56105-81-8 (R) -2-(3-benzaylphenyl)propionic acid 
22161-86-0 • {RS)~2-{3-benzoylphenyl)propionic acid 
78834-75-0 ethyl 7-chloro-2-cocoheptanoate 
1944-S3-4 3- [ (3aS,4S,7aS)-7a-methyl-l,S-dioxoactahydro-
lH-inden-4-yl]propionic acid 
39562-17-9 methyl 2-(3-nitrobenzylidene)-3-oxobutyrate 
2918 90 90 26159-31-9 (RS)-2-(6-methoxy-2-naphchyl)propionic, acid 
105560-93-8 methyl (2R,3S)-2,3-epoxy-3-(4-
methoxyphenyl)propionate 
40098-26-8 methyl 7-[(3RS)-3-hydrpxy-S-oxocyclopent-l-
enyl]heptanoate 
2921 19 so 4261-68-1 (2-chloroethyl)diisopropylamine hydrochloride 
2921 59 90 122-75-8 N,N'-dibenzylethylenediammonium di(acetate) 
2922 19 00 126456-43-7 (IS, 2R)-l-aminoindan-2-ol 
68047-07-4 4'-[2-(dimethylamino)ethoxy]-2-
phenylbutyrophenone 
2922 30 00 784-38-3 2~araino-5-chloro-2'-fluorob«nzophenone 
156732-13-7 (S)-5-amino-2-(dibenzylamino)-l,6~diphenylhex-
4~en73-one 
2922 49 70 37441-29-5 5-amino-2,4,6-triiodoisophthaloyl dichloride 
42854-62-6 ben2yl L-alaninate--p-toluenesulfonic acid 
(1:1) 
39878-87-0 (-)-alpha- (chloroformyl)benzylammonium 
chloride 
54527-73-0 2-(N-methylbenzylamino)ethyl 3 -aminobut-2 -
enoate 
81677-60-3 methyl (4-nitrophenyl)-L-alaninate 
949-99-5 3-(4-nitrophenyl)-L-alanine 
2924 10 00 153758-31-7 (2S)-2-aminb-3-hydroxy-N-pentylpropionamide--
oxalic acid (1:1) 
e 
ANNEX II 
CM code CAS RM Name 
13 8531-07-4 L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lyayl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
lysine 
2924 29 90 4018B-45-2 3'-aoetyl-4'-hydroxybutyranilide 
2924 29 90 1149-26-4 N-(banzyloxycarbonyl)-L-valine 
116661-86-0 (2S,3S)-3-(tert-butoxycarbonylamino)-2-
bydroxy-4-pheiiylbutyric acid 
144163-85-9 tert-butyl [(is,3S,4S)-4-amiao-l-benzyl-3-
hydroxy-5-phenylpentylJcarbamate 
149451-80-9 tert-butyl [(IS,2S)-l-benzyl-2,3-
dihydroxypropyl]carbamate 
98737-29-2 tert-butyl {IS)-alpha-[(S)-
oxiranyl]phenethyl}carbamate 
0-00-0 2-chloro-N-[2-(2-chlorob9nzoyl)-4-
nitrophenyl]acetamide 
125971-96-2 2- [alpha-(4-fluorobenzoyl)benzyl]-4-methyl-3-
oxovaleranilide 
32981-8S-4 methyl (2R,3S)-3-benzamido-2-hydroxy-3-
phenylpropionate 
292.5 19 80 151860-15-0 meeo-N-benzyl-3-nitrocyclopropane-1,2-
dicarboximide 
97338-03-9 «thyl (S)-3-(4-aminophenyl)-2-
phthalimidopropionate hydrochloride 
94213-26-0 ethyl (S)-3-{4-[bis(2-
chloroethyl)amino]phenyl} -2-
phthalimidopropionate hydrochloride 
2926 90 80 58311-73-2 (Z)-(2-cyanovinyl)trimethylammonium p-
toluenesulfonate 
133481-10-4 ethyl (1-cyanocyclohexyl)acetate 
123632-23-5 4-(2,2,3,3 -tetrafluoropropoxy)cinnamon!trile 
2328 00 90 94213-23-7 (Z)-[cyano(2,3-
dichlorophenyl)methylene]carbazamidine 
2930 90 16 159453-24-4 N-(benzyloxycarbanyl)-S-phenyl-L-cysteine 
2930 90 70 159878-02-1 benzyl (1R,2S)-3-chloro-2-hydroxy-l-
(phenylthiomethyl)propylcarbamate 
136511-43-8 ethyl N-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-
oxopropyl}-L-methionate 
2932 19 00 97148-39-5 ammonium (Z)-2-methoxyimino-2-(2-furyl)acetate 
2932 29 80 517-23-7 alpha-acetyl-gamma-butyrolactone 
6559-91-7 4'-demethylepipodophyllotoxin 
3 9521-49-8 (3aR,4bS,4R,4aS,5aS)-4-(5,5-dimethyl-1,3-
dioxolan-2-
yl)hexahydrocyclopropa[3,4]cyclopenta[1,2-
b]furan-2(3H)-one 
39746-Q1-5 (3aR, 4R, 5R, 6aS) -4-formyl-2-oxohaxahydro-2H-
cyclopenta[b]furan-5-yl benzoate 
976-70-5 3-oxopregn-4-ene-21,17-alpha-carbolactone 
2932 99 50 32981-86-5 ia-deacetylbaccatin III 
2932 99 70 7512-17-6 2-acetamido-2-deoxy-beta-D-glucopyranose 
79944-37-9 trans-6-amino-2.2-dimethyl-1,3-dioxepan-5-ol 
125971-94-0 tert-butyl [(4R,6R)-6-(cyanomethyl)-2,2-
dimethyl-i,3-dioxolan-4-yl]acetate 
467-55-0 3-beta-hydroxy-5 -alpha-epiro3tan-12-one 
533-31-3 3,4-(methylenedioxy)phenol 
4t 
ANNEX II 
CM code CAS RM Nana 
2933 11 90 6150-97-6 magnesium bis[(2,3-dihydro-l, 5-dimethyl-3-oxo-
2-phenyl-IH-pyrazol-4 -
yl)methylamino]methanesulfonate 
2933 19 90 27511-79-1 3-aminopyrazole-4-carbaxamide hemisulfate 
2933 29 90 4897-25-0 5~chloro-l-methyl-4-nitroimidazale 
2933 39 95 142057-79-2 (RS)-2-[(l-benzyl-4-piperidyl)methyl]-5,6-
dimethoxyindan-l-one 
120014-07-5 2-[(l-benzyl-4-piperidyl)methylene]-5,6-
dimethoxyindan-1-one 
6 935-27-9 benzyl(2-pyridyl)amine 
87848-95-1 6-bromo-2-pyridyl p-tolyl ketone 
32998-95-1 N-(tert-butyl)-3-methylpyridina-2-carboxamide 
2933 39 95 84449-80-9 1-[2-(4-carboxyphenoxy)ethyl]piperidinium 
chloride 
83949-32-0 4-carboxy-4-phenylpiperidinium p-
coluenesulfonate 
38092-89-6 8-chloro-6,ll-dihydro-11-(l-methyl-4-
piperidylidene)-SH-benzo[5,6]cyclohepta[l,2-
b]pyridine 
31255-57-9 3-[2-(3-chlorophenyl)ethyl]pyridine-2-
carbonitrile 
107256-31-5 3-[2-(3-chlorophenyl)ethyl]-2-pyridyl 1-
methyl-4-piperidyl ketone hydrochloride 
6298-19-7 2-chloro-3-pyridylamine 
5424-11-3 2,2-diphenyl-4-piperidinovaleronitrile 
108555-2S-5 1-[2-(4-methoxyphenyl)ethyl]-4-piperidylamine 
dihydrochloride 
4046-24-6 5-(l-methyl-4-piperidyl)-5H-
dibenzo[a,d]cyclohepten-5-ol hydrochloride 
139886-0^-7 1-methyl-l,2,5,6-t«trahydropyridine-3-' 
carbaldehyde (E)-O-methyloxime hydrochloride 
70708-28-0 1-(2-pyridyl)-3-(pyrrolidin-1-yl)-1-(p-
tolyl)propan-l-ol 
1619-34-7 quinuclidin-3-ol 
2933 40 10 1059S6-96-5 7-[3-{tert-butoxycarbonylamino)pyrrolidin-1-
yl]-8-chloro-l-cyclopropyl-6-fluoro-4-oxo-l,4-
dihydroguinoline-3-carboxylic acid 
86393-33-1 7-chloro-1-cyclopropy1-6-f1uoro-4 -oxo-1,4-
dihydroquinoline-3-carboxylic acid 
H2811-72-0 l-cyclopropyl-6,7-difluoro-B-methoxy-4-oxo-
1,4-dihydroquinoline-3-carboxylic acid 
98349-25-8 ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-l,4-
dihydroquinoline- 3 -carboxylate 
2933 40 90 159878-04-3 benzyl (IS,2B)-3- [ (3S,4aS,8aS)-3-tert-
butylcarbamoylperhydro-2-isoguinolyl]-2-
hydroxy-1-(phenylthiomethyl)propylcarbamate 
15 9989-64-7 (3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S}-2-
hydroxy-3- (3-hydraxy-2~methylbe.nzamido) -4-
(phenylthio)butyl]perhydroisoquinaline-3-
carboxarnide 
15 998 9-65-8 (3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S)-2-
hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
(phenylthio)butyl]perhydroisoquinoline-3-
carboxamide--methane8Ulfonic acid (1:1) 
120578-03-2 3-'[ (E) - 2 - (7 -chloro-2-
quinolyl)vinyl]benzaldehyde 
15 
ANNEX II 
CM code CAS RM H*»« 
1087-69-0 (9S,13S,14S)-3-methoxymorphinan hydrochloride 
64228-78-0 pent ante thyl ene bis{3-[i-(3,4-dimethoxybenzyl)-
6,7-dimathoxy-i,2,3,4-tetrahydro-2-
isoquinolyl]propionate}--oxalic acid (1:2) 
2933 59 70 75128-73-3 2-[(2-acetamido-6-0x0-6,9-dihydro-lH-purin-9-
yDmethoxy] ethyl acetate 
3056-33-5 N- (9-acetyl-6-oxo-6,9-dihydro-lH-purin-2-
yl)acetamide 
10310-21-1 2-amino-6-chloropurine 
124832-31-1 2-[(2-amino-6-oxo-l,6-dihydro-9H-purin-9-
yl)methoxy]ethyl N-(benzyloxycarboayl)-L-
valinate 
150378-17-9 (2R,4S)-2-benzyl-5-[2-(tert-butylcarbamoyl)-4-
(3-pyridylmethyl)piperaz in-1-yl]- 4 -hydroxy-N-
[ (1S.2R)-2-hydroxyindan-l-yl]valeramida 
2933 59 70 157810-81-6 (2R,4S)-2-benzyl-5-[2-(tert-butylcarbamoyl)-4-
(3-pyridylmethyl)piperazin-l-yl]-4-hydroxy-N-
[(IS,2R)-2-hydroxyindan-1-yl]valeramide 
sulfate 
150323-35-6 (3S)-1-(tert-butoxycarbonyl)-3-(tert-
butyl carbamoyl)pipera z ine 
41202-32-8 <l-(2-chlorophenyl)piperazine hydrochloride 
13078-15-4 1-(3-chlorophenyl)piperazine hydrochloride 
71-30-7 cytoaine 
149062-75-9 1,3-dlchlorO-6,7,8,9,10, 12-
hexahydroazepino[2,l-b]quinazoline 
hydrochloride 
,41202-77-1 1-(2, 3-dichlorophenyl)piperazine hydrochloride 
56177-80-1 2-ethoxy-5-fluorapyrimidin-4(1H)-one 
112733-45-6 ethyl (7-chloro-2,4-dioxo-l, 2 , 3 , 4-
tetrahydroquinazolin-1-yl)acetate 
59703-00-3 4-ethyl-2,3-dioxopiperazine-l-carbonyl 
chloride 
64090-19-3 1-(4-fluorophenyl)piperazine dihydrochloride 
147539-21-7 i3opropyl[2-(piperazin-1-yl)-3-pyridyl]amine 
35386-24-4 1-(2-methoxyphenyl)piperazine 
5464-78-8 1-(2-methoxyphenyl)piperazine hydrochloride 
145012-50-6 (7RS,9aRS)-perhydropyrido[l,2-a]pyrazin-7-
ylmethanol 
2210-93-7 1-phenylpiperaziniura chloride 
111641-17-9 4-(piperazin-1-yl)-2,6-bia(pyrrolidin-I-
yl)pyrimxdine 
68-94-0 purin-6(1H)-one 
70849-60-4 1-(o-tolyl)piperazine hydrochloride 
2933 69 80 58909-39-0 tetrahydro-2-methyl-3-thioxo-l,2,4-criazine-
5.6-dione 
2933 79 00 135297-22-2 (3S,4R)-3-[(R)-1-(tert-
butyldimethylsilyloxy)ethyl]-4-[(lR,3S)-3-
methoxy-2-oxocyclohexyl]azetidin-2-one 
141646-08-4 l-{[(cyclohexyloxy)carbonyl]oxy}ethyl l-(l-
hydroxyethyl)- 5-methoxy-2-oxo-
1,2,5,6,7,8,8a,8b-octahydroazeto[2,1-
a]isoindale-4-carboxylate 
132127-34-5 (3R,4S)-3-hydroxy-4-phenylazetidin-2-one 
75363-99-4 p-nitrobenzyl (2R.5R,6S)-6-[(R)-l-
hydroxyethyl]-3,7-dioxo-l-
ANNEX II 
CM code CAS RM 
azabicyclo[3 .2 . o] hop tane-2-car boxy late 
141316-45-2 potassium l-(1-hydroxyethyl)-5-raethoxy-2-oxo-
1,2,5,6,7,8,8a,8b-octahydroazeto[2,1-
a]isoindole-4-carboxylate 
2933 90 60 59467-64-0 [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-lH-
1,4-benzodiazepin-2-yl]methylamine 
59469-29-3 [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-lH-
l,4-benzodiazepin-2-ylmethyl]ammonium 
bis(maleate) 
59467-69-5 8-chloro-6-(2-fluorophenyl)-l-methyl-3a,4-
dihydro-3H-imidazo[l', 5-a] [1, 4] benzodiazepine 
5946 9-63-5 7-chloro-5-(2-fluorophenyl)-3-methyl-2-
(nitromethylene)-2,3-dihydro-lH-l,4-
benzodiazepine 4-oxide 
59467-63-9 7-chloro-5-(2-fluorophenyl)-2-
(nitromethylene)-2,3-dihydro-lH-l, 4-
benzodiazapine 
2933 90 95 130404-91-0 N-[(R)-2-({(R)-2-[(2-
adamantyloxycarbonyl)amino]-3-(lH-indol-3-yl)-
2-methyl-1-oxopropyl}amino) -1 -
phenylethyl]succinamic acid--i-deoxy-l-
methylamino-D-glucitol (1:1) 
122536-48-5 3-[(S)-3-(L-alanylamino)pyrrolidin-i-yl]-i-
cyclopropyl-6-fluoro-4-oxo-l, 4-dihydro-l,8-
naphthyridine-3-carboxylic acid hydrochloride 
122536-91-8 7-{(S)-3-[(S)-2-(tert-butoxycarbonylamino)-l-
oxopropylamino]pyrrolidin-1-yl}-l-cyclopropyl-
6-fluoro-4-oxo-l,4-dihydro-l,8-naphthyridine-
3-carboxylic acid 
134575-17-0 tert-butyl meso-3-azabicyclo[3.1.0]hex-6-
ylcarbamate 
122536-66-7 tert-butyl { (S) -l-methyl-2-oxo-2- [ (S) -1 
pyrrolidin-3-ylamino]ethyl}carbamate 
140629-77-2 tert-butyl [(RS)-pyrrolidin-3-yl]carbamate 
100361-18-0 7-chloro-l-cyclopropyl-6-fluoro-4-oxo-l,4-
dihydro-1,8-naphthyridine-3-carhoxylic acid 
38150-27-5 S-chloro-2-[3-(hydroxymethyl)-5-methyl-4H-
1,2,4-triazol-4-yl]benzophenone 
36916-19-5 5-chloro-2- (3r-methyl-4H-l, 2 ,4-triazol-4-
yl )benzophenone 
54196-62-2 2' , 5-dichloro-2- [3- (hydroxymethyl) -5-mathyl-
4H-1,2,4-triazol-4-yl]benzophenone 
54196-61-1 2',5-dichloro-2-(3-methyl-4H-1,2,4-triazol-4-
yl)benzophenone 
141113-28-2 (E)-(+)-2-(2,4-difluorophenyl)-l-{3-[4-
(2,2,3,3-tecrafluoropropoxy)styryl]-1H-1,2,4-
triazol-i~yl}-3-(1H-1,2,4-triazol-l-yl)propan • 
2-ol 
141113-41-9 (R)-2-(2,4-difluorophenyl)-3-(1H-1, 2,4-
triazol-l-yl)propane-l,2-diol 
144034-80-0 dimethyl{2-[5-(1H-1,2,4-triazol-1-
ylmethyl)indol-3-yl]ethyl)amine 
122665-86-5 ethyl [3-(cyanomechyl)-4-oxo-3, 4-
dihydrophthalazin-l-yl]acetate 
41340-36-7 2-(7-ethyl-iH-indol-3-yl)'ethanol 
95885-13-5 5-ethyl-4- (2-phenoxyethyl)-4H-1, 2 . 4»triazol-
^ 
ANNEX II 
CM coda CAS RN Name 
3 (2H) -one 
96107-94-7 ethyl 1H-tetrazole-5-carboxylate, sodium salt 
96034-57-0 trans-4-hydroxy-i-(4-nitrobenzyloxycarbonyl)-
L-proline 
160194-26-3 2-iodo-4-(1H-1,2.4-triazol-l-ylmethyl)aniline 
66635-71-0 isopropyl 2,3-dihydro-lH-pyrrolizine-l-
carboxylate 
4928-88-5 methyl 1H-1,2,4-triazole-3-carboxylate 
0-00-0 1,4,7,10-tetraazacyclododecane-i,4,7-triacetic 
acid sulfate 
112193-77-8 1,4,7,10-tetraazoniacyclododecane bis(sulfate) 
3641-08-5 lH-l,2,4-triazole-3-carboxaroide 
—• —; 4928-87-4 1H-1,2.4-triazole-3-carboxylic acid 
6969-71-7 l,2,4-triazolo[4,3-a]pyridin-3(2H)-one 
2934 10 00 171485-87-3 2-[4-(2-amino-4-oxo-4,5-dihydrothiazol-5-
ylmethyl)phénoxymethyl]-2,5,7,8-
tetramethylchroman-6-yl acetate 
65872-41-5 (Z)-2-(2-aminothiazol-4-yl)-2-
methoxyiminoacetic acid 
64486-18-6 (2)-2-[2-(chloroacetamido)thiazol-4-yl]-2-
(mechoxyimino)acetic acid 
76823-93-3 1-{4-[(2-cyanoethyl)thiomethyl]thiazol-2-
yl}guanidine 
2934 10 00 139340-56-0 (S-[(Z)-3,S-di(tert-butyl)-4-
hydroxybenzylidene]-4-oxo-4,5-dihydrothiazol-
2-yl}ammonium methanesulfonate 
64485-88-7 ethyl (Z)-2-(2-aminothiazol-4-yl)-2 -
(methoxyimino)acetate 
66339-00-2 ethyl 2-(hydroxyimino)-2-[2-
(tritylamino)thiazol-4-yl]acetate 
hydrochloride 
88046-01-9 2-guanidinothiazol-4-ylmethyl 
carbamimidothioate dihydrochloride 
154212-61-0 N-[2-isopropylthiazol-4-
ylmethyl(methyl)carbamoyl]-L-valine 
66215-71-2 (Z)-2-methoxyimino-2-[2-(tritylamino)thiazol-
4-yl]acetic acid 
154212-59-6 4-nitrophenyl thiazol-5-ylmethyi carbonate 
hydrochloride 
38585-74-9 thiazol-5-ylmethanol 
155213-67-5 thiazol-5-ylmethyl (IS,2S,4S)-l-benzyl-2-
hydroxy-4-{(2S)-2-[3-(2-iaopropylthia2ol-4-
ylmethyl) -3-methylureido] -3-methylbuty*;avnido} -
5-phenylpentylcarbamate 
2934 20 50 80756-85-0 S- (benzothiazol-2-yl) (Z)-2- (2-aminotbi-(sol-4-
yl)-2-methoxyiminothioacetate 
2934 20 90 87691-88-1 1-(I,2-bensisothiazdl-3-yl)piperazine 
hydrochloride 
2934. 30 50 111974-69-7 2-(2-[4-(dibenzo [b, f ] [l, 4) thiazepin-i:5-
yl) piperazin-1-yl] ethaxy}atha.nol 
42399-49-5 (3S, 3S) - 3 - hydroxy - 2 - (4-methoxyphenyl) •". ^ 
dihydro-l,5-benzothiazepin-4(5H)-on® 
2934 90 60 115787-67-2 2 » (2-amino-5-nltro-6-oxo-l, 6-dihydropyr : ' ixdi.n-
4-yl) -3- (3-thienyl)propionon.itrile 
117829-20-6 2~amino~7-thenyl-i,7-dihydro-4H-pyrraXoD(3~ 
d]pyrimidin-4.-one hydrochloride 
1 
ANNEX n 
CM coda CAS RM Nam* 
112887-68-0 N-{5-[(1,4-dihydro-2-mcthyl-4-oxoquinazolin-6-
ylmethyl)methylamino]-2-thenoyl}-L-glutamic 
acid 
161005-84-1 (S)-N,N-dimethyl-[3-(2-thienyl)-3-(l-
naphthyloxy)propyl]amine--phosphoric acid 
(1:1) 
104795-66-6 3-isopropoxy-5-methoxy-N-(lH-tetrazol-5-
yl)benzo[b]thiophene-2-carboxamide 
104795-67-7 3-isopropoxy-5-methoxy-N-(lH-tetrazol-5-
yl)benzo[b]thiophene-2-carboxamide--lH-
imidazole (1:1) 
104795-68-8 3-iaopropoxy-5-methoxy-N-(lH-tetrazol-5-
yl)benzo[b]thiophene-2-carboxamide. sodium 
salt 
63675-74-1 6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene 
138564-59-7 5-methyl-2-(2-nitroanilino)thiophene-3-
carbonitrile 
2934 90 70 25229-97-4 2-cyano-3-morpholinoacrylamide 
2934 90 80 119221-49-7 5-[(2-aminoethyl)amino]-2-(2-
diethylaminoethyl)-2H-
(l]benzothiopyrano[4,3,2-cd]indazol-8-ol 
147086-81-5 (43.6S)-5,6-dihydro-6-methyl-4H-thieno[2,3 -
b]thiopyran-4-ol 7,7-dioxide 
2934 90 98 58-61-7 adenosine 
152305-23-2 (S)-4-(4-aminobenzyl)oxazolidin-2-one 
71420-85-4 7-amino-3-[1-(aulforaethyl)-lH-tetrazol-5-
ylthiomethyl]-3-cepham-4-carboxylic acid, 
sodium salt 
29706-84-1 3•' -azido-3 ' -deoxy-5 ' -O-tritylthymidine 
2934 90 98 51762-51-7 benzhydryl 3-hydroxy-7-
(phenylacetamido)cepham-4-carboxylate 
110314-42-6 5-[(benzofuran-2-ylcarbonyl)amino]indole-2-
carboxylic acid 
131986-28-2 3- (4-chloro-l,2, 5-thiadiazol-3-yl)pyridine 
107452-89-1 omega-conotoxin M VIIA 
126429-09-2 2-(dichloromethyl)-4,5-dihydro-5-(4-
meaylphenyl)oxazol-4-ylmethanol 
126813-11-4 (4R,5R)-2-(dichloromethyl)-4.5-dihydro-5-(4-
mesylphenyl)oxazol-4-ylmethanol 
4097-22-7 2',3'-dideoxyadenosine 
139264-17-8 (S)-4-{[3-(2-dimethylaminoethyl)-lH-indol-5-
yl]methyl}oxazolidin-2-one 
110351-94-5 (S) -4-ethyl-4,-hydroxy-7,8-dihydro-lH-
pyrano[3,4-f]indolizine-3,6,10(4H)-trione 
140841-32-3 6- [3-fluora-5-(4-methoxytetrahydropyran-4-
yl)phenoxymethyl]-l-methyl-2-quinolone 
94732-98-6 1-(l-{3-[2-(4-fluorophenyl)-1,3-dioxolan-2-
yl]propyl}-4-piperidyl)-2,3-dihydro-lH-
benzimidazole-2-thione 
125935-03-1 (4R,6R)-G-{2- [2-(4-fluorophenyl)-5-isopropyl-
3-phenyl-4-(phenylcarbamoyl)pyrrol-1 -
yl]ethyl}-4-hydroxytetrahydro-2H-pyran-2-one 
131988,-19-7 3- (4-hexyloxy-l,2. S-thiadiazol-3-yl! -1-
methylpyridinium iodide 
147027-10-9 (1R,2S,5R)-menthyl (2R,5S)-5-(4-amino-2-oxo-
l, 2-dihydropyrimidin-l-yl)-1,3-oxathiolane-2-
ANNEX II 
CM code CAS RM Mane 
147126-62-3 
104218-44-2 
27255-72-7 
0-00-0 
32231-06-4 
55612-11-8 
2935 00 90 151140-66-8 
112101-81-2 
120298-38-6 
1S0975-9S-4 
84522-34-9 
2939 10 00 66820-84-6 
2940 00 90 13035-61-5 
3824 90 64 330-95-0 
104832-01-1 
0-00-0 
3824 90 64 0-00-0 
0-00-0 
0-00-0 
3824 90 95 0-00-0 
3911 90 162430-94-6 
3913 90 80 83513-48-8 carboxylate 
(1R,2S,5R)-menthyl (2R,5R)-5-hydroxy-1,3-
oxathiolane-2-carboxylate 
3'-0-mesyl-5'-O-tritylthymidine 
3-methyl-7-(phenylacetamido)-3-cephem-4-
carboxylic acid 
(1R,2S,3S,6R)-[(S)-l-phenylethyl]-3.6-
epoxyt et rahydrophtha1imide 
1-piperonylpiperaziiMS 
5 *-O-tritylthymidine 
(4-amino-3-iodophenyl)-N-
methylmethanesulfonamide 
5-[(R)-(2-aminopropyl)]-2-
methoxybenzeneaulfonamide 
N-(5,6-dihydro-6-methyl-2-sulfamoyl-4H~ 
thieno[2,3-b]thiopyran-4-yl)acetamide 7,7-
dioxide 
5-methanesulfonamidoindole-2-carboxy1ic acid 
sodium 4-[2-(5-methylpyrazine-2-
carboxamido)ethyl]benzenesulfonamide 
(RS)-tetrahydropapaverine hydrochloride 
1,2.3,5-tetraacetyl-beta-D-ribofuranose 
1,3-bis(4-nitrophenyl)urea- -4,6-
dimathylpyrimidin-2-ol (1:1) 
(R)-6,7-dimethoxy-2-methyl-1-(3,4,5-
trimethoxybenzyl)-1,2, 3,4-
tetrahydroisoquinoline--dibenzoyl-L-tartaric 
acid (1:1) 
Intermediate concentrate obtained from a 
genetically-modified Escherichia coli 
fermentation medium, containing human 
granulocyte-macrophage colony-stimulating 
factor,- for use in the manufacture of 
medicaments of HS Mo. 3002 
Intermediate concentrate obtained from a 
genetically-modified Escherichia coli 
fermentation medium, containing human 
interferon alpha-2b; for use in the 
manufacture of medicaments of HS No. 3002 
Intermediate concentrates obtained from a 
Micromonospora inyoensis fermentation medium 
used for the manufacture of the antibiotics 
sisomiein (INN) and netilmicin (INN) 
Intermediate concentrates obtained from a 
Micromonospora purpurea fermentation medium 
used for the manufacture of the antibiotics 
gentaraicin sulfate (ÏNNM) and isepamicin (INN) 
ethyl 7-chloro-2-oxoheptanoate, in the form of 
a solution in toluene 
1,6-hexanediamine, polymer with 1,10-
dibromodecane 
danaparoid sodium 
c2o 
Annex III 
Additions to the list of prefixes and suffixes which, in combination with the INNs, 
describe salts, esters or hydrates of INNs. 
51 
ACETURATE 
N-ACETYLGLYCINATE 
ACISTRATE 
ACOXIL 
AMSONATE 
BENZATHINE 
BEZOMIL 
BUCICLATE 
BUNAPSILATE 
BUTEPRATE 
BUTYL ESTER 
CARBESILATE 
p-CHLOROBENZENESULFONATE 
p-CHLOROBENZENESULPHONATE 
CICLOTATE 
CIPIONATE 
CLOSILATE 
CLOS YL ATE 
CROBEFATE 
CROMACATE 
CROMESILATE 
CYCLOPENTANEPROPIONATE 
CYCLOTATE 
CYPIONATE 
DAPROPATE 
DEANIL 
DECIL 
DIBUDINATE 
DIBUNATE 
DIETHANOLAMINE 
DIGOLIL 
N,N-DIMETHYL-beta-ALANINE 
DIOLAMINE 
DOCOSEL 
DOFOSFATE 
EDAMINE 
EDISYLATE 
EPOLAMINE 
ERBUMINE 
ETABONATE 
ETHANOLAMINE 
ETHYLENEDIAMINE 
FARNESIL 
FENDIZOATE 
FOSTEDATE 
HIBENZATE 
HYBENZATE 
HYCLATE 
o-(4-HYDROXYBENZOYL)BENZOATE 
ISOCAPROATE 
LAURIL 
LAURILSULFATE 
LAURILSULPHATE 
LAURYL 
LAURYLSULFATE 
LAURYLSULPHATE 
MEGALLATE 
METEMBONATE 
4-METHYLBICYCLO[2.2.2]OCT-2-ENE-l-CARBOXYLATE 
MOFETIL 
OCTIL 
OLAMINE 
OXOGLURATE 
PENDETIDE 
n 
PIVOXETIL 
PROXETIL 
1 -PYRROLIDINEETHANOL 
SODIUM LAURIL SULFATE 
SODIUM LAURIL SULPHATE 
SODIUM LAURYL SULFATE 
SODIUM LAURYL SULPHATE 
STEAGLATE 
TENOATE 
TEPROSILATE 
TETRADECYL HYDROGEN PHOSPHATE 
TOFESILATE 
TRICLOFENATE 
TRIETHANOLAMINE 
TRIFLUTATE 
TROLAMINE 
TROMETAMOL 
TROMETHAMINE 
TROXUNDATE 
XINAFOATE 
% 
l\ Annex IV 
INNs which shall no longer benefit from duty free treatment 
CN code 
2903 22 00 
2903 30 10 
2903 51 10 
2906 21 00 
2915 29 00 
2922 41 00 
2922 42 90 
2922 49 10 
2922 50 00 
2923 10 10 
2928 00 90 
2930 90 20 
2933 90 95 
3102 70 10 
3904 61 10 
3906 90 90 
3907 20 
3907 20 12 
3907 20 21 
3907 60 10 
3908 10 00 
3910 00 00 
3912 20 11 
3912 31 00 
3912 39 80 CAS RN 
79-01-6 
811-97-2 
58-89-9 
100-51-6 
82279-57-0 
56-87-1 
56-86-0 
56-40-6 
72-19-5 
67-48-1 
79-17-4 
111-48-8 
73-22-3 
156-62-7 
9002-84-0 
54182-57-9 
0-00-0 
25322-68-3 
25301-02-4 
25038-59-9 
25038-54-4 
9006-65-9 
9004-70-0 
9000-11-7 
8063-82-9 Name 
trichloroethylene 
norflurane 
lindane 
benzyl alcohol 
zinc acetate, basic 
lysine 
glutamic acid 
glycine 
threonine 
choline chloride 
pimagedine 
thiodiglycol 
tryptophan 
calcium carbimide 
politef 
carbomer 
macrogol ester 
macrogol 
tyloxapol 
pegoterate 
policapram 
dimeticone 
pyroxylin 
carmellose 
hypromellose 
ISSN 0254-1475 
COM(96) 563 final 
DOCUMENTS 
EN 02 05 09 15 
Catalogue number : CB-C0-96-562-EN-C 
ISBN 92-78-10884-7 
Office for Official Publications of the European Communities 
L-2985 Luxembourg 
25